Update on angiogenesis inhibitors

Anaadriana Zakarija, Gerald Soff*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

75 Scopus citations

Abstract

Purpose of review: A number of therapeutic agents have been developed which have anti-angiogenic potential. Here we present the most recent data from clinical trials with some of the promising inhibitors of angiogenesis. Recent findings: Agents that target the vascular endothelial growth factor signaling pathway are the furthest along in clinical development. The last year has brought US Food and Drug Administration approval of bevacizumab (Avastin), a recombinant humanized anti-vascular endothelial growth factor monoclonal antibody. Bevacizumab has demonstrated a survival advantage in combination with chemotherapy for patients with metastatic colorectal cancer. Other agents with early promising results include PTK787/ZK 222584 (Vatalanib), ZD6474, and BAY 43-9006 (Sorafenib). Summary: Angiogenesis inhibitors show promise, but evaluation for optimal efficacy has been a problem, given that the mechanisms of action of these agents differ from conventional cytotoxic agents and surrogate markers for inhibition of angiogenesis are not available.

Original languageEnglish (US)
Pages (from-to)578-583
Number of pages6
JournalCurrent opinion in oncology
Volume17
Issue number6
DOIs
StatePublished - Nov 1 2005

Keywords

  • Angiogenesis
  • Cancer treatment
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Update on angiogenesis inhibitors'. Together they form a unique fingerprint.

Cite this